Found 19 Non-Hodgkin's Lymphoma trials
A listing of Non-Hodgkin's Lymphoma medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
This is a global Phase 2, open-label, single-arm, multicohort, multicenter study to evaluate efficacy and safety of JCAR017 in adult subjects with r/r FL or MZL.
This trial is an open-label, multicenter, Phase 1b/2 trial investigating Hu5F9-G4 + rituximab (antibody combination) in R/R B-cell non-Hodgkins lymphoma (NHL) and Hu5F9-G4 + R-GemOx (chemotherapy combination) in indolent lymphoma and diffuse large B cell lymphoma (DLBCL)
The goal of this trial is to evaluate the safety of autologous genetically modified TC-110 T cells in adult patients with aggressive NHL (DLBCL, PMBCL, TFL, MCL), high-risk indolent NHL, or ALL. And to establish the recommended phase 2 dose (RP2D) for the NHL and ALL indications according to the …
Non-Hodgkin lymphoma is a disease that can be treated effectively with chemotherapy and immunotherapy, but relapses can occur. The purpose of this study is to research the use of a new radioimmunotherapy drug called Betalutin®. Betalutin® is made by using a new antibody, called lilotomab, and attaching a radioactive molecule …
Please refer to the protocol Section 3 (Objectives and Endpoints) Please refer to the protocol Section 3 (Objectives and Endpoints) Please refer to the protocol Section 3 (Objectives and Endpoints)
We would like to rely on the WIRB as IRB of record for this study. The main purpose of this study is to find out if the investigational therapy tisagenlecleucel (i.e. CTL019, CART-19, or Kymriah®) is safe and has beneficial effects in people who have relapsed or refractory aggressive B-cell …
Please refer to Section 2 of the full protocol (Study Objectives). Please refer to Section 8.1 of the full protocol (Study Endpoints). Please refer to Section 8.1 of the full protocol (Study Endpoints).
This study plans to treat subjects with pembrolizumab by infusion in combination with radiation therapy to see if the combination is an effective treatment for relapsed/refractory non-Hodgkin lymphoma. Radiation therapy is commonly used to treat relapsed/refractory non-Hodgkin lymphoma. Although pembrolizumab is FDA-approved for some cancers, including Hodgkin lymphoma, it is …
Patients with plasmablastic lymphoma are potential participants of this research trial. Patients with a type of B-cell non-Hodgkin lymphoma (NHL) will be invited from Penn Medicine practices. This research study is designed to test the safety of daratumumab, a drug added to the standard lymphoma treatment when given to individuals …
The study will assess how safe and well-tolerated a combination of the study drugs itacitinib and everolimus in patients with Hodgkin lymphoma. We also hope to learn how effective this experimental combination is in treating Hodgkin lymphoma, when given together.
1 - 10 of 19
- 1
- 2
